Article thumbnail

The efficacy and safety of nutrient supplements in the treatment of mental disorders : a meta-review of meta-analyses of randomized controlled trials

By Joseph (R19072) Firth, Scott B. Teasdale, Kelly Allott, Dan J. Siskind, Wolfgang Marx, Jack Cotter, Nicola Veronese, Felipe B. Schuch, Lee Smith, Marco Solmi, Andre F. Carvalho, Davy Vancampfort, Michael Berk, Brendon Stubbs and Jerome (R18802) Sarris


The role of nutrition in mental health is becoming increasingly acknowledged. Along with dietary intake, nutrition can also be obtained from “nutrient supplements”, such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, amino acids and pre/probiotic supplements. Recently, a large number of meta-analyses have emerged examining nutrient supplements in the treatment of mental disorders. To produce a meta-review of this top-tier evidence, we identified, synthesized and appraised all meta-analyses of randomized controlled trials (RCTs) reporting on the efficacy and safety of nutrient supplements in common and severe mental disorders. Our systematic search identified 33 meta-analyses of placebo-controlled RCTs, with primary analyses including outcome data from 10,951 individuals. The strongest evidence was found for PUFAs (particularly as eicosapentaenoic acid) as an adjunctive treatment for depression. More nascent evidence suggested that PUFAs may also be beneficial for attention-deficit/hyperactivity disorder, whereas there was no evidence for schizophrenia. Folate-based supplements were widely researched as adjunctive treatments for depression and schizophrenia, with positive effects from RCTs of high-dose methylfolate in major depressive disorder. There was emergent evidence for N-acetylcysteine as a useful adjunctive treatment in mood disorders and schizophrenia. All nutrient supplements had good safety profiles, with no evidence of serious adverse effects or contraindications with psychiatric medications. In conclusion, clinicians should be informed of the nutrient supplements with established efficacy for certain conditions (such as eicosapentaenoic acid in depression), but also made aware of those currently lacking evidentiary support. Future research should aim to determine which individuals may benefit most from evidence-based supplements, to further elucidate the underlying mechanisms

Topics: XXXXXX - Unknown, mental health, schizophrenia, depression, dietary supplements, unsaturated fatty acids, omega-3 fatty acids, eicosapentaenoic acid
Publisher: U.K., John Wiley & Sons
Year: 2019
DOI identifier: 10.1002/wps.20672
OAI identifier: oai:nuws:uws_53133
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.